No Data
KeyBanc Maintains Recursion Pharmaceuticals(RXRX.US) With Buy Rating, Maintains Target Price $12
Recursion Pharmaceuticals Analyst Ratings
Strategic Mergers and Financial Strength: Recursion Pharmaceuticals' Path to Growth
Recursion Pharmaceuticals' Strategic Acquisition and Leadership Changes
Recursion and Exscientia, Two Leaders in the AI Drug Discovery Space, Have Officially Combined to Advance the Industrialization of Drug Discovery
Nvidia Reveals 3.6% Stake In Applied Digital, Stock Soars
No Data
No Data
